Tag: Simcyp
Towards Quantitative Prediction of Disease-drug Interactions Using a Physiologically-based Pharmacokinetic Modeling Approach: Suppression of CYP1A2 by IL-6
Extended Validation of a Peripheral Sampling Site in PBPK Modeling Using Clarithromycin, Dextromethorphan, Dextrorphan, Erythromycin, Lidocaine and Tramadol
Certara Launches its Cardiac Safety Simulator V2.0
New biosimulation solution addresses drug candidates’ cardiotoxicity risk PRINCETON, NJ – Apr. 2, 2015 – Certara®, the global biosimulation technology-enabled consultancy, today announced the launch of version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is currently being used by several leading pharma companies, two … Continued
Certara Promotes Prof. Amin Rostami to Senior Vice President of R&D and Chief Scientific Officer
Rostami is recognized for his scientific leadership, original thinking, and commitment to knowledge sharing with his colleagues and students PRINCETON, NJ – Jan. 29, 2015 – Certara®, the global biosimulation technology-enabled drug development and drug safety consulting company, today announced that it has promoted Amin Rostami, Pharm.D., Ph.D. to senior vice president (SVP) of R&D … Continued
Certara Updates its Simcyp Simulator Used to Predict Drug Behavior in Virtual Patient Populations
Simcyp Simulator advances drug development and regulatory approval for majority of top 40 pharma companies PRINCETON, NJ – Nov. 19, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that it has released version 14 of its Simcyp™ Population-based Simulator, which enables biopharmaceutical researchers to predict drug-drug interactions and … Continued
Quantitative Prediction of Human Dermal Absorption from In Vitro/In Silico Data Using Simcyp Simulator—Importance of Ionization at Skin Surface and Binding to Keratin Along with the Thickness and Lipid Levels of Skin Layers
Physiologically-based IVIVC at a Population Level—Deconvoluting In Vivo Dissolution and Identifying Sources of Variability
Certara Receives FDA Grant to Enhance Simcyp Simulator’s Mechanistic Dermal Absorption Model
Enhanced solution will be able to model additional populations, and diseases, and also consider new mechanisms that impact dermal absorption. ST. LOUIS, MO – Oct. 23, 2014 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced that it has received a Food and Drug Administration (FDA) Office of Generic Drugs … Continued
